Association between 1 Homozygous Deletion and Risk of Pancreatic Cancer: A Meta Analysis.

Author: Jun-Peng CUI ¹ ; Mei-Yi LIN ² ; Zheng-Hao LIU ³ ; Bao-Lin LIU ³
Author Information

1. Sixth Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
2. Department of Rheumatology, First Affiliated Hospital of China Medical University, Shenyang 110001, China.
3. China Medical University, Shenyang 110013, China.
Publication Type:Journal Article
From: Chinese Medical Sciences Journal 2019;34(3):205-210
CountryChina
Language:English
Abstract: Objective To clarify the possible association of 1 homozygous deletion with the susceptibility to pancreatic cancer. Methods We searched PubMed database, Chinese Journal Full Text Database (CNKI), and EMBASE to find the eligible studies published up to April 18, 2018 for evaluating the relationship between 1 homozygous deletion and pancreatic cancer. The frequency of null genotype for 1 between the pancreatic cancer group and the healthy control group was compared with - test, and odds ratios (s) value and 95% confidence interval (95% ) were calculated. Results A total of 9 studies met the inclusion criteria, and 5952 cases consisting of 2387 pancreatic cancer patients and 3565 healthy controls were included in the meta analysis. Compared with the control group, frequency of null genotype for 1 in the pancreatic cancer group was higher (33.4% . 38.7%, = 1.26, 95% = 1.01-1.58, = 0.04). Conclusion 1 homozygous deletion individuals may have higher susceptibility to pancreatic cancer.